According to a recent LinkedIn post from Actithera, the company has appointed Marion Masitsa M. as Director of RLT Discovery and Preclinical Sciences to lead its team in Oslo. The post highlights her extensive expertise in advancing next‑generation radioligand therapies and frames the hire as an important addition to the organization’s scientific leadership.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For investors, this senior appointment suggests Actithera is reinforcing its research capacity in radioligand therapy, a modality attracting increasing biotech and pharma interest. Strengthening preclinical leadership in Oslo could support pipeline progression, improve the quality of early‑stage assets, and potentially enhance the company’s positioning for partnerships or future funding in the radiopharmaceuticals space.